<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="214861">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00288574</url>
  </required_header>
  <id_info>
    <org_study_id>#4703R</org_study_id>
    <secondary_id>R01MH060271</secondary_id>
    <secondary_id>R01MH060336</secondary_id>
    <secondary_id>DSIR AT-P</secondary_id>
    <nct_id>NCT00288574</nct_id>
  </id_info>
  <brief_title>Fluoxetine to Prevent Relapse and Enhance Psychological Recovery in Women With Anorexia Nervosa</brief_title>
  <official_title>Fluoxetine After Weight Restoration in Anorexia Nervosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <brief_summary>
    <textblock>
      This study will evaluate the effectiveness of fluoxetine versus placebo in reducing the rate
      of relapse of anorexia nervosa (AN) and enhancing the psychosocial and behavioral recovery
      of people who have been treated for AN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anorexia nervosa (AN), a type of eating disorder, is a serious psychiatric illness that is
      characterized by an extreme loss of appetite. People with AN view themselves as overweight
      and cannot bring themselves to eat, even though most are dangerously thin. Signs of the
      disorder include unusual eating habits, such as avoiding food and meals, picking out a few
      foods and eating them in small quantities, or carefully weighing and portioning food. Some
      people with AN fully recover after a single episode, some have a fluctuating pattern of
      weight gain and relapse, and others experience a chronic course of illness over many years.
      Effective drugs to treat the disorder are lacking. In addition, most past research has
      examined the effect of medications during the initial phase of treatment, a time when AN
      patients may not respond to medication because of the acute effects of starvation.
      Fluoxetine is a selective serotonin reuptake inhibitor (SSRI) that is commonly used to treat
      depression. This study will evaluate the effectiveness of fluoxetine versus placebo in
      reducing the rate of relapse of AN and enhancing the psychosocial and behavioral recovery of
      women who have already been treated for AN.

      Participants in this double-blind study will be recruited immediately following completion
      of a treatment program for AN, in which they maintained a body mass index (BMI) of at least
      19 kg/m2 for two weeks. Upon study entry, participants will be randomly assigned to receive
      either fluoxetine or placebo for 12 months. Participants will begin receiving medication one
      week prior to discharge from the hospital in which they received care for AN. Medication
      doses will be increased up to a target dose of 60 mg per day, and will not exceed 80 mg per
      day. Participants will receive 50 sessions of cognitive-behavioral therapy, lasting
      approximately 45 minutes each and occurring twice weekly for the first month following
      discharge from the hospital. After the first month, therapy sessions will occur once weekly
      until Month 9 and then every other week until Month 12. Participants will also report to the
      study site to meet with a psychiatrist once a week for the first month following discharge
      and then every other week for the remainder of the study. General medical status, evidence
      of AN relapse, medication dose, and side effects will be assessed at these visits. Upon
      completing treatment, follow-up telephone calls will occur at Months 15 and 21, and
      follow-up visits will be held at Months 18 and 24. Psychopathology associated with AN,
      including concern with weight and shape, depressive symptoms, anxiety, and obsessive
      behavior, will be assessed.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Patients Remaining in Study at 1 Year</measure>
    <time_frame>12 months</time_frame>
    <description>The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining &gt; 85% Ideal Body Weight.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>Anorexia Nervosa</condition>
  <condition>Eating Disorders</condition>
  <arm_group>
    <arm_group_label>fluoxetine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>fluoxetine up to 80 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluoxetine</intervention_name>
    <arm_group_label>fluoxetine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Meets DSM-IV criteria for anorexia nervosa (except the requirement for amenorrhea)

          -  Successfully completed treatment at one of the study sites in an inpatient or
             day-program setting immediately prior to study entry (BMI remained at least 19 kg/m2
             for two weeks)

        Exclusion Criteria:

          -  Currently taking any medications other than occasional lorazepam or zopiclone for
             anxiety or sleep disturbance

          -  Previous serious adverse reactions to fluoxetine (e.g., allergy)

          -  Currently at risk for suicide

          -  Any medical condition requiring treatment with other psychotropic medication (except
             the occasional use of anti-anxiety medication)

          -  Pregnant

          -  Any serious medical illness besides the eating disorder

          -  History of continuous illness (at a low weight with no periods of remission or return
             to normal functioning for more than 15 years)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>B. Timothy Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York State Psychiatric Institute/Columbia University Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allan Kaplan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Toronto General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute/Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W. Fluoxetine after weight restoration in anorexia nervosa: a randomized controlled trial. JAMA. 2006 Jun 14;295(22):2605-12. Erratum in: JAMA. 2006 Aug 23;296(8):934. JAMA. 2007 Nov 7;298(17):2008.</citation>
    <PMID>16772623</PMID>
  </results_reference>
  <verification_date>March 2015</verification_date>
  <lastchanged_date>May 26, 2016</lastchanged_date>
  <firstreceived_date>February 6, 2006</firstreceived_date>
  <firstreceived_results_date>September 8, 2015</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anorexia Nervosa</mesh_term>
    <mesh_term>Feeding and Eating Disorders</mesh_term>
    <mesh_term>Anorexia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluoxetine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluoxetine</title>
          <description>fluoxetine up to 80 mg per day
Fluoxetine</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
                <participants group_id="P2" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluoxetine</title>
          <description>fluoxetine up to 80 mg per day
Fluoxetine</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo group</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
            <count group_id="B2" value="44"/>
            <count group_id="B3" value="93"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.4" spread="4.46"/>
                    <measurement group_id="B2" value="24.2" spread="4.52"/>
                    <measurement group_id="B3" value="23" spread="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Proportion of Patients Remaining in Study at 1 Year</title>
        <description>The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining &gt; 85% Ideal Body Weight.</description>
        <time_frame>12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fluoxetine</title>
            <description>fluoxetine up to 80 mg per day
Fluoxetine</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo group</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Patients Remaining in Study at 1 Year</title>
          <description>The primary outcome measure was the proportion of patients with AN successfully completing 1 year of treatment and maintaining &gt; 85% Ideal Body Weight.</description>
          <units>percentage of patients</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                    <measurement group_id="O2" value="31.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Approximately weekly clinician interview over one year</desc>
      <group_list>
        <group group_id="E1">
          <title>Fluoxetine</title>
          <description>fluoxetine up to 80 mg per day
Fluoxetine</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Medication</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>suicide attempt</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="49"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>BT Walsh, MD</name_or_title>
      <organization>NYSPI</organization>
      <phone>646-774-8066</phone>
      <email>edru@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
